Startup Professionals Musings

OCTOBER 26, 2018

New technology markets and paradigm shifts have traditionally been bad bets when seeking investors, since these were known to take decades to develop, and cost lots of money. Marty Zwilling First published on CayenneConsulting on 10/10/2018. The leading edge was too often the bleeding edge.

Marketing 92

Marketing Demand Examples Social Media 92

Xconomy

AUGUST 16, 2019

billion in 2018, and Novartis reportedly knew but failed to report it to the FDA before the agency approved Zolgensma in May. We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7

Report 63

Report Activity San Diego Study 63

Xconomy

NOVEMBER 11, 2016

CRISPR DEVELOPMENTS. —Oral arguments in the landmark patent fight over ownership of the gene editing technology CRISPR-Cas9 were set for Dec. Patent and Trademark Office. —Despite the patent fight, CRISPR work continues apace. —Despite the patent fight, CRISPR work continues apace. 6 at the U.S.

Patents 87

Patents Study Pricing Research 87